Open Access

SET and MYND domain‑containing protein 3 inhibits tumor cell sensitivity to cisplatin

  • Authors:
    • Lei Wang
    • Man‑Li Xu
    • Chang Wang
    • Qing‑Qing Dong
    • Zhi Miao
    • Xiao‑Ying Chen
    • Nan Wang
    • Hong‑Peng He
    • Tong‑Cun Zhang
    • Xue‑Gang Luo
  • View Affiliations

  • Published online on: March 19, 2020     https://doi.org/10.3892/ol.2020.11465
  • Pages: 3469-3476
  • Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cisplatin resistance has been a major factor limiting its clinical use as a chemotherapy drug. The present study aimed to investigate whether SET and MYND domain‑containing protein 3 (SMYD3), a histone methyltransferase closely associated with tumors can affect the sensitivity of tumors to cisplatin chemotherapy. Real time‑qPCR, western blotting, the luciferase reporter, MTT and clonogenic assays were performed to detect the effects of SMYD3 on the chemotherapy capacity of cisplatin. In the present study, SMYD3 exhibited different expression patterns in MCF‑7 and T47D breast cancer cells. In addition, this differential expression was associated with tumor cell resistance to cisplatin. Furthermore, SMYD3 knockdown following small interfering RNA transfection increased cisplatin sensitivity, whereas SMYD3 overexpression decreased cisplatin sensitivity. In addition, SMYD3 knockdown synergistically enhanced cisplatin‑induced cell apoptosis. SMYD3 expression was downregulated during cisplatin treatment. In addition, transcriptional regulatory activities of SMYD3 3'‑untranslated region were also downregulated. These results suggested that SMYD3 may affect cell sensitivity to cisplatin and participate in the development of cisplatin resistance, which is a process that may involve microRNA‑124‑mediated regulation.

Related Articles

Journal Cover

May 2020
Volume 19 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Wang, L., Xu, M., Wang, C., Dong, Q., Miao, Z., Chen, X. ... Luo, X. (2020). SET and MYND domain‑containing protein 3 inhibits tumor cell sensitivity to cisplatin. Oncology Letters, 19, 3469-3476. https://doi.org/10.3892/ol.2020.11465
MLA
Wang, L., Xu, M., Wang, C., Dong, Q., Miao, Z., Chen, X., Wang, N., He, H., Zhang, T., Luo, X."SET and MYND domain‑containing protein 3 inhibits tumor cell sensitivity to cisplatin". Oncology Letters 19.5 (2020): 3469-3476.
Chicago
Wang, L., Xu, M., Wang, C., Dong, Q., Miao, Z., Chen, X., Wang, N., He, H., Zhang, T., Luo, X."SET and MYND domain‑containing protein 3 inhibits tumor cell sensitivity to cisplatin". Oncology Letters 19, no. 5 (2020): 3469-3476. https://doi.org/10.3892/ol.2020.11465